Separately, ANKTIVA secured regulatory approval in Macau SAR, marking the drug's first international market clearance and the beginning of ex-U.S. commercialization. But the bull case now runs directly into a regulatory wall: the FDA issued a warning letter over misleading promotional claims for ANKTIVA, triggering sharp selling — IBRX is down ~35.8% since last earnings. The stock has whipsawed as investors try to price positive clinical and international milestones against a concrete FDA enforcement action.
Watch for two things: the timeline on the supplemental filing to FDA in the BCG-naïve setting, and whether the warning letter escalates beyond a letter into further enforcement. The spread between those two outcomes defines the risk/reward from here.
ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month
NEW YORK, April 10 —
ImmunityBio's Anktiva bladder cancer trial cleared a key statistical hurdle, but an FDA warning letter just wiped $2bn off the stock.
- Q1 2026 net product revenue hit $44.2mn, up 168% YoY and 15% QoQ from $38.3mn in Q4 2025
- Stock at $7.34 with a negative 367x forward P/E. BTIG holds a Buy rating with a $13 price target, nearly double current levels
- Supplemental BLA submission for BCG-naive NMIBC on track for 2026. IDMC confirmed trial is adequately powered at N=366
What Actually Happened
Two things happened, and they contradict each other. First, the good news: the Independent Data Monitoring Committee reviewed interim complete response data on 183 evaluable patients in the QUILT-2.005 trial. The study compares Anktiva plus BCG versus BCG alone in BCG-naive bladder cancer patients. The IDMC confirmed the trial has enough statistical power to detect pre-specified differences. No additional enrollment is needed. The supplemental BLA remains on track for 2026, which would expand Anktiva's label beyond its current BCG-unresponsive approval into the much larger BCG-naive population.
Then came the blow. On March 13, the FDA's Office of Prescription Drug Promotion sent a warning letter calling ImmunityBio's promotional materials "false or misleading." The specific problem: a podcast featuring CEO Patrick Soon-Shiong in which he claimed Anktiva "can actually treat all cancers." The FDA said the materials "grossly misrepresent the benefits of Anktiva" — a drug approved for one specific type of bladder cancer. The stock fell 21% on March 24 when the letter went public. Securities class action lawsuits followed within days.
The Catch
The bull case treats this as a promotion compliance problem, not a product safety problem. BTIG kept its Buy rating and $13 target, calling it something that "can likely be resolved" based on historical precedent. Piper Sandler carries an Overweight rating and $12 target, projecting $195mn in 2026 Anktiva revenue. The company had $381mn in cash at quarter end, bolstered by $75mn in non-dilutive funding from Oberland.
The bear case is blunter: the CEO went on a podcast and told cancer patients his drug treats all cancers. That's not a paperwork error. It's the kind of statement that draws prolonged FDA scrutiny over every future promotional activity. With levered free cash flow still at negative $213mn over the trailing twelve months, ImmunityBio needs every quarter of clean commercial execution it can get. A company burning $200mn+ a year can't afford distractions from its own CEO.
Bottom Line
The trial data is strong. BCG-naive NMIBC is a bigger market than BCG-unresponsive, and clearing the statistical power check keeps the supplemental filing on schedule. But the FDA warning raises a question that has nothing to do with science and everything to do with whether management can stay out of its own way. What matters now is the FDA's response timeline — specifically, whether the warning escalates beyond a letter. If it stays at the promotion compliance level, the stock at $7.34 trades at a steep discount to $13 analyst targets. If it escalates, the lawsuits stop looking like ambulance-chasing and start looking like real liability.
For a deeper look at ImmunityBio's financials and valuation, generate a free Basis Report on IBRX.
Basis Report does not hold positions in securities discussed. This is not investment advice.